Novo Nordisk, Eli Lilly to slash prices for popular weight loss drugs – TODAY

Novo Nordisk, Eli Lilly to slash prices for popular weight loss drugs  TODAY

Clinical briefing: the rise of weight loss drugs – Pharmacy Magazine

Clinical briefing: the rise of weight loss drugs  Pharmacy Magazine

Minnesota mulls insurance mandate for weight-loss drugs – Axios

Minnesota mulls insurance mandate for weight-loss drugs  Axios

Can Neoadjuvant Semaglutide Boost Bariatric Surgery Results? – Medscape

Can Neoadjuvant Semaglutide Boost Bariatric Surgery Results?  Medscape

Motivating Patients to Follow a Healthy Lifestyle on GLP-1s – Medscape

Motivating Patients to Follow a Healthy Lifestyle on GLP-1s  Medscape

Novo Nordisk to slash weight-loss drug Wegovy prices – Semafor

Novo Nordisk to slash weight-loss drug Wegovy prices  Semafor

Novo Nordisk to test GLP-1’s impact on addiction (NVO:NYSE) – Seeking Alpha

Novo Nordisk to test GLP-1’s impact on addiction (NVO:NYSE)  Seeking Alpha

You’ve Already Paid $6 Billion For Weight-Loss Drugs You Can’t Afford – The Lever

You’ve Already Paid $6 Billion For Weight-Loss Drugs You Can’t Afford  The Lever

The Billion-Dollar Taxpayer Math Behind The Ozempic Boom – The Lever

The Billion-Dollar Taxpayer Math Behind The Ozempic Boom  The Lever

Beyond compliance: The strategic role of PASS in rare disease therapy success

Post-authorisation safety studies (PASS) are often seen simply as a regulatory necessity, a checkbox that ensures…